This is a prospective, multicenter single arm study designed to evaluate the effectiveness and safety of a predefined oral corticosteroids (OCS) tapering schedule to reduce OCS use in adult participants with acetylcholine receptor positive (AChR+) generalized myasthenia gravis (gMG) being treated with intravenous ravulizumab.

Inclusion Criteria:

• Aged greater than 18 years and male or female
• Clinical diagnosis of gMG
• Receiving ravulizumab treatment prior to enrollment
• Receipt of OCS therapy equivalent to a daily dose ≥ 7.5 mg of prednisone/prednisolone for ≥ 4 continuous weeks directly preceding enrollment
• A participant of childbearing potential must have a negative highly sensitive pregnancy test (serum or urine, as required by local regulations) taken at Screening before OCS tapering begins.
• Willing to sign informed consent

Exclusion Criteria:

• Concurrent participation in an interventional clinical trial.
• History of chronic hypoadrenalism (ie, Addison's disease).
• Use of concomitant OCS for comorbid conditions other than gMG
• Receipt of a biologic for gMG (e.g., efgartigimod, rozanolixizumab, inebilizumab, rituximab, intravenous immunoglobulin) within 5 half-lives of enrollment
• Pregnant, breastfeeding, or intending to conceive during the course of the study

Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.